Autonomix Announces 83% Reduction of Pain at 4-6 Week Follow-Up from Lead-In Patients in Ongoing Human Clinical Trial in Pancreatic Cancer Pain Patients
Autonomix Medical, Inc. (AMIX)
Company Research
Source: GlobeNewswire
Responders experienced a pain reduction from a pre-procedure pain score of 8 to a pain score of 1.33 at 4-6 weeks post-procedure 60% of patients responded with a mean 6.67 or 83% reduction of pain on the VAS pain scale (from baseline of 8.0 to 1.33) at 4-6 weeks post-procedure 100% of this responder group had clinically meaningful pain relief at 4-6 weeks post-procedure Trial remains on track to complete enrollment by year-end 2024 THE WOODLANDS, TX, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced 4-6 week preliminary positive results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept human clinical trial (the “Trial”) evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patie
Show less
Read more
Impact Snapshot
Event Time:
AMIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMIX alerts
High impacting Autonomix Medical, Inc. news events
Weekly update
A roundup of the hottest topics
AMIX
News
- Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner SegmentGlobeNewswire
- Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum [Yahoo! Finance]Yahoo! Finance
- Autonomix Selected to Present at the 2024 Octane Medical Innovation ForumGlobeNewswire
- Autonomix Medical, Inc. (NASDAQ: AMIX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $1.40 price target on the stock.MarketBeat
- Autonomix Medical, Inc. to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
AMIX
Sec Filings
- 9/20/24 - Form 8-K
- 9/5/24 - Form DEFA14A
- 9/4/24 - Form DEF
- AMIX's page on the SEC website